DUKE UNIVERSITY
Immunomodulation in AAV gene therapy
Immunomodulation in AAV gene therapy is a funding opportunity from DUKE UNIVERSITY, up to 3192404, closing July 31, 2029.
Jul 31, 2029
(1096d left)Overview
Abstract Recombinant AAV vectors have emerged as promising gene delivery vehicles in the treatment of monogenic disorders. With 6 different FDA approved AAV-based therapies, many additional disease targets requiring systemic dosing continue advancing towards the clinic. However, immune responses arising from prior…